Study Information

Title: A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer External
Status: Recruiting participants
Conditions: Non-Small Cell Lung Cancer (ALK-positive); Non-Small Cell Lung Cancer (c-Met-amplified); Non-Small Cell Lung Cancer (ROS Marker Positive); Systemic Anaplastic Large-Cell Lymphoma; Advanced Malignancies (Except Leukemia)
Interventions: Drug: PF-02341066; Drug: Rifampin; Drug: Itraconazole
Institutions: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Joslin Diabetes Center, Massachusetts General Hospital
Health Topics: Adenocarcinoma of the Lung, Lung Cancer Overview, Non-Hodgkin Lymphoma, Squamous cell carcinoma of the lung

Contact Information

Beth Israel Deaconess Medical Center
Boston, MA 02215
Dana Farber Cancer Center
Boston, MA 02215
Joslin Beetham Eye Institute
Boston, MA 02215
Massachusetts General Hospital
Boston, MA 02114
Ophthalmic Consultants of Boston Inc.
Boston, MA 02114